Showing results (3141-3150 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|March 2, 2024
Clinical immunotherapy in pancreatic cancerXiaorong Ye, Yue Yu, Xiaohu Zheng, et al.Cancer Immunology, Immunotherapy : CII|March 2, 2024
Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinomaXinru Fan, Zijun Yan, Yunkai Lin, et al.Cancer Immunology, Immunotherapy : CII|March 2, 2024
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinomaTanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, et al.Cancer Immunology, Immunotherapy : CII|March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancerGerald S Falchook, James Reeves, Sunil Gandhi, et al.Cancer Immunology, Immunotherapy : CII|February 17, 2024
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched studyHui-Min Lian, Jia-Liang Wu, Wei-Jian Liufu, et al.Cancer Immunology, Immunotherapy : CII|November 8, 2023
The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progressionNicola E Annels, M Denyer, D Nicol, et al.Cancer Immunology, Immunotherapy : CII|November 8, 2023
Spatial immune composition of tumor microenvironment in patients with pancreatic cancerEline S Zwart, Thomas van Ee, Alsya J Affandi, et al.Cancer Immunology, Immunotherapy : CII|November 9, 2023
Esophageal cancer cell-derived small extracellular vesicles decrease circulating Tfh/Tfr via sEV-PDL1 to promote immunosuppressionZijie Li, Yuehua Zhang, He Hao, et al.Cancer Immunology, Immunotherapy : CII|November 6, 2023
Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemiaQian Peng, Renhua Huang, Huiping Wang, et al.Cancer Immunology, Immunotherapy : CII|November 4, 2023
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agentsMaria Livia Del Giudice, Sara Galimberti, Gabriele BudaPageof 652